Get the Stockscreener App
66.06
0.26%
-0.17
After Hours:
62.20
-3.86
-5.84%
Ptc Therapeutics Inc stock is traded at $66.06, with a volume of 1.04M.
It is down -0.26% in the last 24 hours and up +8.14% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$66.23
Open:
$66.23
24h Volume:
1.04M
Relative Volume:
0.82
Market Cap:
$5.25B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-11.12
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+1.94%
1M Performance:
+8.14%
6M Performance:
+53.70%
1Y Performance:
+69.38%
1-Day Range:
$65.85
$67.03
1-Week Range:
$62.32
$67.24
52-Week Range:
$35.51
$67.40
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
66.06 | 5.26B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
How PTC Therapeutics Inc. stock compares to growth peersWeekly Trade Review & Fast Moving Stock Trade Plans - newser.com
Using RSI to spot recovery in PTC Therapeutics Inc.Weekly Stock Recap & Accurate Entry/Exit Alerts - newser.com
Live market analysis of PTC Therapeutics Inc.Quarterly Earnings Report & High Conviction Buy Zone Alerts - newser.com
Relative strength of PTC Therapeutics Inc. in sector analysis - newser.com
Using flow based indicators on PTC Therapeutics Inc.Market Activity Summary & Daily Profit Maximizing Trade Tips - newser.com
PTC Therapeutics, Inc. Hits New 52-Week High of $67.40 - Markets Mojo
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 3,375 Shares of Stock - MarketBeat
PTC Therapeutics' (PTCT) Hold (C-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Chart based analysis of PTC Therapeutics Inc. trendsQuarterly Performance Summary & Fast Entry and Exit Trade Plans - newser.com
Ptc Therapeutics exec. VP Boulding sells $214k in shares By Investing.com - Investing.com Canada
What does recent volatility data suggest for PTC Therapeutics Inc.Weekly Stock Report & Short-Term High Return Ideas - newser.com
Robeco Institutional Asset Management B.V. Buys Shares of 5,733 PTC Therapeutics, Inc. $PTCT - MarketBeat
RBC Raises Price Target on PTC Therapeutics to $70 From $63, Keeps Outperform Rating - MarketScreener
Mark Elliott Boulding Sells 2,266 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Allan Steven Jacobson Sells 12,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Sells $3,632,750.00 in Stock - MarketBeat
Allan Jacobson sells PTC Therapeutics shares for $780,000 - Investing.com
Ptc therapeutics exec. VP Boulding sells $1.6m in stock - Investing.com
Emma Reeve, PTC Therapeutics director, sells $1.68m in shares - Investing.com
Duchenne Muscular Dystrophy Market Report 2034: Epidemiology, Pipeline Therapies, and Recent Regulatory Approvals by DelveInsight | Featuring Sarepta Therapeutics, PTC Therapeutics, Nippon Shinyaku, S - Barchart.com
Real time breakdown of PTC Therapeutics Inc. stock performance2025 Earnings Surprises & Low Drawdown Investment Strategies - newser.com
Evaluating PTC Therapeutics Inc. with trendline analysisJuly 2025 Setups & Verified Technical Signals - newser.com
PTC Therapeutics Stock Sees Momentum Amidst Corporate Developments - StocksToTrade
PTC Therapeutics Bolsters Workforce Amid Stock Option Grants - timothysykes.com
Analysts Shine Spotlight on PTCT in Friedreich’s Ataxia Talks - timothysykes.com
Why PTC Therapeutics Inc. (BH3) stock could outperform next yearDollar Strength & Reliable Intraday Trade Alerts - newser.com
Will PTC Therapeutics Inc. (BH3) stock outperform energy sector in 2025 - newser.com
How to build a custom watchlist for PTC Therapeutics Inc.Quarterly Portfolio Review & High Conviction Trade Alerts - newser.com
Will PTC Therapeutics Inc. rebound enough to break evenCEO Change & Weekly Momentum Picks - newser.com
Is PTC Therapeutics Inc. (BH3) stock among top earnings plays2025 Price Momentum & AI Enhanced Trading Signals - newser.com
PTC Therapeutics Announces New Employee Stock Grants Amid Strategic Developments - timothysykes.com
PTCT Sees Strategic Staff Expansion Amidst Recent Developments - timothysykes.com
Will uniQure’s Results Pressure PTC Therapeutics’ (PTCT) Rare Disease Leadership and Revenue Ambitions? - Sahm
Using AI based signals to follow PTC Therapeutics Inc.2025 Historical Comparison & Reliable Intraday Trade Plans - newser.com
Ptc Therapeutics stock hits 52-week high at 63.33 USD By Investing.com - Investing.com Nigeria
PTC Therapeutics (NASDAQ:PTCT) Hits New 1-Year HighWhat's Next? - MarketBeat
Ptc Therapeutics stock hits 52-week high at 63.33 USD - Investing.com India
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
19,475 Stock Options, 39,060 RSUs: PTC Therapeutics Awards Major Inducement Grants to New Employees - Stock Titan
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):